vs

Side-by-side financial comparison of Invesco (IVZ) and Sunrun Inc. (RUN). Click either name above to swap in a different company.

Invesco is the larger business by last-quarter revenue ($1.7B vs $1.2B, roughly 1.5× Sunrun Inc.). Sunrun Inc. runs the higher net margin — 8.9% vs -58.9%, a 67.8% gap on every dollar of revenue. On growth, Sunrun Inc. posted the faster year-over-year revenue change (123.5% vs 6.2%). Over the past eight quarters, Sunrun Inc.'s revenue compounded faster (59.0% CAGR vs 7.1%).

Invesco Ltd. is an American independent investment management company headquartered in Atlanta, Georgia, with branch offices in 20 countries. Its common stock is a constituent of the S&P 500 and trades on the New York Stock Exchange. Invesco operates under the Invesco, Invesco Perpetual, and Powershares brand names.

Sunrun Inc. is an American provider of photovoltaic systems and battery energy storage products, primarily for residential customers. The company was established in 2007 and is headquartered in San Francisco, California.

IVZ vs RUN — Head-to-Head

Bigger by revenue
IVZ
IVZ
1.5× larger
IVZ
$1.7B
$1.2B
RUN
Growing faster (revenue YoY)
RUN
RUN
+117.3% gap
RUN
123.5%
6.2%
IVZ
Higher net margin
RUN
RUN
67.8% more per $
RUN
8.9%
-58.9%
IVZ
Faster 2-yr revenue CAGR
RUN
RUN
Annualised
RUN
59.0%
7.1%
IVZ

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IVZ
IVZ
RUN
RUN
Revenue
$1.7B
$1.2B
Net Profit
$-995.9M
$103.6M
Gross Margin
Operating Margin
-86.2%
8.4%
Net Margin
-58.9%
8.9%
Revenue YoY
6.2%
123.5%
Net Profit YoY
-575.8%
103.7%
EPS (diluted)
$-2.61
$0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVZ
IVZ
RUN
RUN
Q4 25
$1.7B
$1.2B
Q3 25
$1.6B
$724.6M
Q2 25
$1.5B
$569.3M
Q1 25
$1.5B
$504.3M
Q4 24
$1.6B
$518.5M
Q3 24
$1.5B
$537.2M
Q2 24
$1.5B
$523.9M
Q1 24
$1.5B
$458.2M
Net Profit
IVZ
IVZ
RUN
RUN
Q4 25
$-995.9M
$103.6M
Q3 25
$356.4M
$16.6M
Q2 25
$197.4M
$279.8M
Q1 25
$171.1M
$50.0M
Q4 24
$209.3M
$-2.8B
Q3 24
$55.0M
$-83.8M
Q2 24
$132.2M
$139.1M
Q1 24
$141.5M
$-87.8M
Operating Margin
IVZ
IVZ
RUN
RUN
Q4 25
-86.2%
8.4%
Q3 25
16.5%
0.5%
Q2 25
14.1%
-19.7%
Q1 25
18.1%
-22.8%
Q4 24
19.6%
-628.0%
Q3 24
6.6%
-23.8%
Q2 24
13.9%
-24.4%
Q1 24
14.4%
-40.0%
Net Margin
IVZ
IVZ
RUN
RUN
Q4 25
-58.9%
8.9%
Q3 25
21.7%
2.3%
Q2 25
13.0%
49.1%
Q1 25
11.2%
9.9%
Q4 24
13.1%
-542.7%
Q3 24
3.6%
-15.6%
Q2 24
8.9%
26.5%
Q1 24
9.6%
-19.2%
EPS (diluted)
IVZ
IVZ
RUN
RUN
Q4 25
$-2.61
$0.38
Q3 25
$0.66
$0.06
Q2 25
$-0.03
$1.07
Q1 25
$0.38
$0.20
Q4 24
$0.46
$-12.59
Q3 24
$0.12
$-0.37
Q2 24
$0.29
$0.55
Q1 24
$0.31
$-0.40

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVZ
IVZ
RUN
RUN
Cash + ST InvestmentsLiquidity on hand
$1.0B
Total DebtLower is stronger
$1.8B
$14.7B
Stockholders' EquityBook value
$12.2B
$3.1B
Total Assets
$27.1B
$22.6B
Debt / EquityLower = less leverage
0.15×
4.69×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVZ
IVZ
RUN
RUN
Q4 25
$1.0B
Q3 25
$973.1M
Q2 25
$922.7M
Q1 25
$821.7M
Q4 24
$986.5M
Q3 24
$1.0B
Q2 24
$878.5M
Q1 24
$895.7M
Total Debt
IVZ
IVZ
RUN
RUN
Q4 25
$1.8B
$14.7B
Q3 25
$1.6B
$14.6B
Q2 25
$1.9B
$14.0B
Q1 25
$964.8M
$13.6B
Q4 24
$890.6M
$12.9B
Q3 24
$890.3M
$12.5B
Q2 24
$890.1M
$12.0B
Q1 24
$1.3B
$11.1B
Stockholders' Equity
IVZ
IVZ
RUN
RUN
Q4 25
$12.2B
$3.1B
Q3 25
$14.0B
$3.0B
Q2 25
$13.9B
$2.9B
Q1 25
$14.7B
$2.6B
Q4 24
$14.6B
$2.6B
Q3 24
$14.8B
$5.3B
Q2 24
$14.6B
$5.4B
Q1 24
$14.6B
$5.2B
Total Assets
IVZ
IVZ
RUN
RUN
Q4 25
$27.1B
$22.6B
Q3 25
$28.4B
$22.2B
Q2 25
$28.5B
$21.2B
Q1 25
$28.1B
$20.4B
Q4 24
$27.0B
$19.9B
Q3 24
$27.5B
$22.1B
Q2 24
$27.2B
$21.4B
Q1 24
$28.1B
$20.8B
Debt / Equity
IVZ
IVZ
RUN
RUN
Q4 25
0.15×
4.69×
Q3 25
0.12×
4.90×
Q2 25
0.14×
4.80×
Q1 25
0.07×
5.19×
Q4 24
0.06×
5.05×
Q3 24
0.06×
2.36×
Q2 24
0.06×
2.23×
Q1 24
0.09×
2.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVZ
IVZ
RUN
RUN
Operating Cash FlowLast quarter
$455.8M
$96.9M
Free Cash FlowOCF − Capex
$432.2M
FCF MarginFCF / Revenue
25.5%
Capex IntensityCapex / Revenue
1.4%
Cash ConversionOCF / Net Profit
0.94×
TTM Free Cash FlowTrailing 4 quarters
$1.4B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVZ
IVZ
RUN
RUN
Q4 25
$455.8M
$96.9M
Q3 25
$606.2M
$-121.5M
Q2 25
$547.9M
$-292.7M
Q1 25
$-84.6M
$-104.2M
Q4 24
$316.9M
$-258.4M
Q3 24
$438.4M
$-156.2M
Q2 24
$489.1M
$-208.5M
Q1 24
$-54.4M
$-143.1M
Free Cash Flow
IVZ
IVZ
RUN
RUN
Q4 25
$432.2M
Q3 25
$586.4M
Q2 25
$530.4M
Q1 25
$-108.0M
Q4 24
$309.9M
Q3 24
$410.0M
$-156.4M
Q2 24
$462.4M
Q1 24
$-75.4M
FCF Margin
IVZ
IVZ
RUN
RUN
Q4 25
25.5%
Q3 25
35.7%
Q2 25
35.0%
Q1 25
-7.1%
Q4 24
19.5%
Q3 24
27.1%
-29.1%
Q2 24
31.2%
Q1 24
-5.1%
Capex Intensity
IVZ
IVZ
RUN
RUN
Q4 25
1.4%
Q3 25
1.2%
Q2 25
1.2%
Q1 25
1.5%
Q4 24
0.4%
Q3 24
1.9%
0.0%
Q2 24
1.8%
Q1 24
1.4%
Cash Conversion
IVZ
IVZ
RUN
RUN
Q4 25
0.94×
Q3 25
1.70×
-7.33×
Q2 25
2.78×
-1.05×
Q1 25
-0.49×
-2.08×
Q4 24
1.51×
Q3 24
7.97×
Q2 24
3.70×
-1.50×
Q1 24
-0.38×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IVZ
IVZ

Investment Advice$1.2B73%
Distribution And Shareholder Service$382.7M23%
Financial Service Other$51.0M3%
Investment Performance$28.9M2%

RUN
RUN

Products$692.3M60%
Customer Agreements$435.2M38%
Manufactured Product Other$56.7M5%
Incentives$31.3M3%

Related Comparisons